Daisy Lau

Daisy is a Senior Research Manager based in Rotterdam. Her expertise lies in coordinating large multi-country projects in the healthcare arena, conducting both quantitative and qualitative research. Having worked with pharmaceutical, medical device and other B2B companies, she holds deep knowledge of the analytical techniques and software required for methodology design, execution and interpretation. Daisy holds a Biology degree from Simon Fraser University, B.C., Canada.
Find me on:

Recent Posts

Achieving big impact with small HCP samples

By Daisy Lau on April 02, 2019

How to unlock the numbers in niche indications by using Multi-Criteria Decision Analysis

If you’re in a highly specialized area, such as MedTech or rare diseases, you’ll be only too familiar with the challenges of working with small sample sizes. Qualitative insights are important but when go/no go decisions are at stake, you may need a more data-driven approach. But, how can you obtain robust market data for decision-making when your target population and treating physicians are limited?

Having worked with leading pharma companies over the years, our team recognizes the issues that small samples present. Since we never want to sacrifice analytical rigor, especially when key milestones in product development are involved, we realized this was a dilemma we wanted to tackle. Always keen to explore (and validate) new research techniques, we’re recommending a creative approach that addresses small HCP samples and delivers big value. Here, I’ll explain how leveraging a little used tool in pharma market research – Multi-Criteria Decision Analysis (MCDA) – can reap a big impact. 

Continue Reading